Amiodarone neuropathy is nerve damage caused by amiodarone, one of the most widely prescribed antiarrhythmic drugs used to control dangerous heart rhythms. It typically shows up as numbness, tingling, weakness, or pain in the hands and feet, and it develops gradually over months to years of treatment. A large retrospective study at the Mayo Clinic found that roughly 3% of patients treated with amiodarone developed some form of neurotoxicity, with peripheral neuropathy among the most common manifestations.1JAMA Neurology. Frequency, Characteristics, and Risk Factors for Amiodarone Neurotoxicity The condition is treatable, but the first step in treatment is recognizing it, and that turns out to be harder than it should be.
How Common Is It
Estimates of how often amiodarone causes nerve problems vary enormously depending on how you look. The Mayo Clinic study tracked 707 patients over about 12 years and found a cumulative incidence of about 2.8% for all neurotoxic effects, including tremor, gait problems, cognitive changes, and peripheral neuropathy.1JAMA Neurology. Frequency, Characteristics, and Risk Factors for Amiodarone Neurotoxicity Other studies and case series put the rate much higher. A review of published case reports and clinical trials found neurotoxicity rates ranging from under 2% to over 50%, depending on the study design, the dose used, and how actively clinicians looked for nerve damage.2Journal of Pharmacy Technology. Amiodarone-Induced Neuropathies and Related Neurotoxicities
That spread is not as contradictory as it sounds. Studies that relied on patients volunteering their symptoms tended to find low rates, because early neuropathy is easy to dismiss or overlook. Studies that actively tested patients with nerve conduction studies found subclinical abnormalities in a much larger fraction. The practical takeaway is that mild, undiagnosed nerve changes are probably more common than the headline figures suggest, and clinically significant neuropathy that actually disrupts daily life sits somewhere in the low single digits of patients on long-term therapy.
What Symptoms to Watch For
Amiodarone neuropathy typically follows a “stocking-and-glove” pattern: symptoms start in the toes and feet, then creep upward toward the ankles and eventually the hands. The earliest complaints are usually tingling, numbness, or a burning sensation in the feet. As the condition progresses, weakness sets in. One case report described an 87-year-old woman whose hip flexors had weakened to the point where she could barely lift her legs, and her knee extensors were substantially impaired, all in the setting of chronic amiodarone use.3PubMed Central. Amiodarone-induced neuromyopathy in a geriatric patient Her case also showed signs of muscle damage alongside the nerve damage, a combination called neuromyopathy that is not unusual with amiodarone.
Beyond the limbs, amiodarone can cause other neurological problems that sometimes coexist with peripheral neuropathy. The Mayo Clinic study found that the full spectrum of amiodarone neurotoxicity includes tremor, difficulty walking due to poor coordination, and cognitive impairment.1JAMA Neurology. Frequency, Characteristics, and Risk Factors for Amiodarone Neurotoxicity A patient might notice their handwriting getting shakier, their balance feeling off, or their thinking becoming foggy, all alongside the numbness in their feet. These symptoms tend to build so slowly that patients and even their doctors attribute them to aging or other medications.
Why Amiodarone Damages Nerves
Amiodarone is an unusual drug in many ways, and one of the most important is its extraordinarily long half-life. Once it builds up in body tissues, it can take weeks to months to clear even after the drug is stopped. It accumulates heavily in fat-rich tissues, and nerve tissue has a lot of fat, particularly in the myelin sheaths that insulate nerve fibers and allow signals to travel quickly.
The damage starts in Schwann cells, the cells responsible for producing and maintaining myelin in peripheral nerves. Autopsies and nerve biopsies from affected patients consistently show the same hallmark finding: dense, layered structures called lamellated inclusion bodies packed inside the cells of the nerve. These inclusions are lysosomal in origin and are essentially storage deposits of undigested lipids (fats) that the cell’s normal recycling machinery can no longer break down.4PubMed. The pathology of amiodarone neurotoxicity. II. Peripheral neuropathy in man The same type of inclusions have been found in Schwann cells, fibroblasts, and blood vessel cells within the nerve, a pattern consistent with other drug-induced lipid storage disorders.5Journal of the Neurological Sciences. Peripheral neuropathy induced by amiodarone chlorhydrate: A clinicopathological study
Laboratory work on cultured Schwann cells has filled in more of the picture. Amiodarone causes a dose- and time-dependent buildup of phospholipids and other fats inside these cells, triggers oxidative stress, and impairs the cells’ ability to break down their own waste through a process called autophagy. Eventually, the Schwann cells detach from the nerve fibers they are supposed to protect, and the myelin sheaths break down.6PubMed. Involvement of oxidative stress and impaired lysosomal degradation in amiodarone-induced schwannopathy Nerve biopsies from patients bear this out: the primary finding is demyelination with relatively mild loss of the nerve fibers themselves, at least initially.4PubMed. The pathology of amiodarone neurotoxicity. II. Peripheral neuropathy in man In advanced cases, though, the axons themselves begin to degenerate, which is why late-stage amiodarone neuropathy can be harder to reverse.
What Makes Some Patients More Vulnerable
The single most consistent risk factor is how long you take the drug. The Mayo Clinic study specifically looked at whether age, dose, sex, or the reason the drug was prescribed predicted neurotoxicity, and none of those factors were as important as duration of treatment.1JAMA Neurology. Frequency, Characteristics, and Risk Factors for Amiodarone Neurotoxicity An early case series also noted that peripheral neuropathy appeared after more than 18 months of therapy at high doses.7PubMed Central. Peripheral neuropathy during longterm high-dose amiodarone therapy
That said, dose does matter in practice. Case reports describe neuropathy across a wide range of doses, from 200 mg per day (a common maintenance dose) all the way up to 1,200 mg per day, and across treatment durations from as short as two and a half months to as long as 20 years.2Journal of Pharmacy Technology. Amiodarone-Induced Neuropathies and Related Neurotoxicities The cumulative amount of drug your body absorbs over time is what drives the toxicity. Research into amiodarone’s lung toxicity reinforces this idea: even patients on lower daily doses can develop problems if they stay on the drug long enough, because the cumulative exposure keeps rising.8PubMed Central. A multicenter retrospective cohort study on predicting the risk for amiodarone pulmonary toxicity The same logic applies to nerve damage.
Patients who already have some degree of nerve vulnerability, such as those with diabetes, chronic kidney disease, or other medications that can stress nerves, are likely at higher risk, although large studies isolating these individual factors for neuropathy specifically are limited. Age is often mentioned as a risk factor in clinical discussion, but the Mayo data did not find it to be independently significant once duration of therapy was accounted for.
How It Is Diagnosed
There is no blood test or imaging scan that definitively says “this is amiodarone neuropathy.” Diagnosis relies on pattern recognition: a patient on amiodarone develops progressive neuropathy symptoms, other common causes are investigated and either ruled out or deemed insufficient to explain the findings, and the timeline fits.
Nerve conduction studies and electromyography (EMG) are the standard tests used to characterize the damage. In classic amiodarone neuropathy, these tests show a length-dependent pattern, meaning the longest nerves (those running to the feet) are affected first and most severely. The predominant finding is usually demyelination, reflecting the drug’s primary attack on Schwann cells, though axonal damage can be present as well. One case report described severe axonal length-dependent polyneuropathy in the lower extremities along with evidence of direct muscle damage.3PubMed Central. Amiodarone-induced neuromyopathy in a geriatric patient Another documented a non-length-dependent demyelinating polyneuropathy, showing that the pattern is not always textbook.9PubMed Central. Uncommon neuromyopathy toxicity induced by amiodarone therapy: case report
A nerve biopsy, typically of the sural nerve at the ankle, can show the characteristic lamellated inclusion bodies that are essentially a fingerprint of amiodarone toxicity. In practice, biopsies are done only when the diagnosis is uncertain or when ruling out other demyelinating conditions is important. Most patients are diagnosed clinically based on the combination of symptoms, electrical test results, drug exposure history, and improvement after the drug is stopped.
The real diagnostic challenge is not confirming the neuropathy but connecting it to amiodarone rather than the many other causes of neuropathy in the typical amiodarone patient population, which skews older and often carries multiple other medical conditions. Diabetes, vitamin deficiencies, kidney disease, alcohol use, and other medications can all cause similar symptoms. A careful medication timeline and willingness to consider amiodarone as the culprit are essential.
Treatment and Recovery
The primary treatment is stopping amiodarone or, when that is not possible because of dangerous heart rhythm problems, reducing the dose to the lowest effective level. Because amiodarone has such a long tissue half-life, improvement does not happen overnight. It can take weeks to months for symptoms to begin improving after the drug is discontinued, and some patients take a year or more to reach their best recovery.
The Mayo Clinic study noted that neurotoxic effects were “usually but not always reversible” when they could be assessed.1JAMA Neurology. Frequency, Characteristics, and Risk Factors for Amiodarone Neurotoxicity This tracks with what we know about the underlying damage: when the problem is primarily demyelination with the nerve fibers still intact, Schwann cells can regenerate myelin and function returns. When axonal damage has occurred, recovery is slower, incomplete, or sometimes absent, because regrowing nerve fibers is a much harder biological task than re-wrapping existing ones.
There is no specific antidote or reversal agent for amiodarone neuropathy. Supportive treatments target symptoms: medications for nerve pain (gabapentin, pregabalin, duloxetine, and similar drugs used for other neuropathies), physical therapy to maintain strength and balance, and occupational therapy if hand function is affected. If muscle weakness is significant, as in the neuromyopathy variant, rehabilitation becomes especially important to prevent falls and maintain mobility while waiting for nerve recovery.
The decision to stop amiodarone is not always straightforward. The drug is frequently prescribed for life-threatening arrhythmias where alternatives are limited or have already failed. Cardiologists and neurologists sometimes need to negotiate a difficult trade-off between the risk of continued nerve damage and the risk of uncontrolled heart rhythm. In some cases, a dose reduction rather than full discontinuation is the compromise, though the evidence that lower doses fully prevent ongoing neurotoxicity is not strong.
Amiodarone and the Optic Nerve
Amiodarone can also damage the optic nerve, a condition known as amiodarone-associated optic neuropathy. This is a distinct problem from peripheral neuropathy, but it shares the same underlying mechanism of lipid accumulation and inclusion body formation within nerve tissue. In the optic nerve, these inclusion bodies appear to obstruct the normal flow of material along the axons, causing the optic disc to swell.10Journal of Integrated Cardiology. Amiodarone induced ischemic optic neuropathy: a case report
The clinical picture is different from typical optic nerve strokes (which cause sudden vision loss in one eye). Amiodarone optic neuropathy tends to come on slowly, affects both eyes at the same time, and features prolonged optic disc swelling that can persist for months.11PubMed Central. Amiodarone-Associated Optic Neuropathy: Clinical Review Patients may notice gradual blurring, loss of color vision, or blind spots. These features help distinguish it from nonarteritic anterior ischemic optic neuropathy, a much more common condition that can coincidentally occur in the same age group taking amiodarone.12JAMA Ophthalmology. Optic Neuropathy in Patients Using Amiodarone The distinction matters because one requires stopping the drug while the other does not.
A patient with peripheral neuropathy from amiodarone should have their vision evaluated as well, since both forms of nerve toxicity can coexist. The drug does not pick and choose which nerves to damage; it accumulates broadly, and the optic nerve and peripheral nerves are both vulnerable.
The Monitoring Gap
Given that amiodarone can damage the thyroid, lungs, liver, eyes, nerves, and skin, clinical guidelines recommend a thorough baseline evaluation before starting the drug and regular monitoring afterward. In practice, adherence to these guidelines is poor, and neurological monitoring is the worst of all.
A study examining how well clinicians followed recommended amiodarone monitoring found that while thyroid and liver function tests were checked before treatment in nearly all patients, not a single patient received a baseline neurological evaluation.13PubMed Central. Adherence to Monitoring Guidelines of Amiodarone Adverse Reactions Baseline eye exams were done in about two-thirds of patients, and ongoing monitoring rates dropped sharply across the board: only about 59% of patients had thyroid function checked every six months, and just 10% got the recommended annual chest X-ray.13PubMed Central. Adherence to Monitoring Guidelines of Amiodarone Adverse Reactions
Structured amiodarone management programs can help. One study comparing patients followed in a dedicated amiodarone monitoring clinic to those receiving usual care found that the clinic group was significantly more likely to receive recommended thyroid and liver function testing.14Journal of Pharmacy Technology. Effectiveness of an Amiodarone Protocol and Management Clinic in Improving Adherence to Amiodarone Monitoring Guidelines These programs typically use checklists and scheduled reminders to ensure tests are not forgotten. Even so, neurological screening remains an afterthought in most settings, partly because there is no simple blood test for it and partly because neuropathy symptoms develop so gradually that neither patients nor prescribers think to raise the issue during routine visits.
If you are taking amiodarone, this is worth knowing. You should not wait for your doctor to ask about numbness, tingling, or weakness in your hands and feet. Bring it up yourself if you notice these symptoms, even if they seem minor. Early detection gives you the best chance of reversing the damage, because the earlier the drug is stopped or reduced, the less axonal injury accumulates.
When Neuropathy Mimics Other Conditions
One reason amiodarone neuropathy gets missed is that it can look like several other conditions common in the same patient population. The typical amiodarone patient is older, often has heart failure or coronary disease, and frequently takes multiple medications. Many of these patients have diabetes, the single most common cause of peripheral neuropathy worldwide. When a 70-year-old with diabetes and atrial fibrillation on amiodarone starts complaining about numb feet, the reflex is to blame the diabetes.
The clue that amiodarone might be the culprit, or at least a contributing factor, is in the timeline and the quality of the nerve damage. Diabetic neuropathy is overwhelmingly axonal on nerve conduction testing, while amiodarone neuropathy often shows prominent demyelinating features, especially earlier in its course. A sudden worsening of previously stable neuropathy symptoms after starting amiodarone, or the development of neuropathy in a patient without other obvious risk factors, should raise suspicion. The appearance of other amiodarone side effects, such as thyroid dysfunction or corneal deposits (which occur in nearly all patients on long-term therapy and are visible on eye exam), can also serve as indirect evidence that the drug is accumulating to toxic levels.
Chronic inflammatory demyelinating polyneuropathy (CIDP) is another condition that can be mimicked, since both CIDP and amiodarone neuropathy can present with demyelinating changes on nerve conduction studies. The distinction matters enormously: CIDP is treated with immunotherapy (steroids, intravenous immunoglobulin), while amiodarone neuropathy is treated by stopping the drug. Misdiagnosing one as the other leads to either unnecessary immunosuppression or failure to address the actual toxin. Nerve biopsy showing the characteristic lamellated inclusions can help resolve ambiguous cases, though as mentioned, this is reserved for genuinely uncertain diagnoses.
Amiodarone’s Muscle Effects
Amiodarone does not limit its toxicity to nerves. It can also directly damage skeletal muscle, a condition that sometimes accompanies the neuropathy and is then termed neuromyopathy. The case of the 87-year-old patient mentioned earlier illustrates this: alongside the severe polyneuropathy, EMG showed myopathic changes in the hip flexor muscles, meaning the muscle fibers themselves were diseased, not just the nerves supplying them.3PubMed Central. Amiodarone-induced neuromyopathy in a geriatric patient
This dual nerve-and-muscle damage can make the weakness disproportionately severe compared to what the nerve damage alone would predict. A patient with mild neuropathy on electrical testing might have dramatic weakness if the muscles are independently affected. Creatine kinase (CK) levels, a blood marker of muscle damage, can be elevated, though a normal CK does not exclude myopathy. Muscle biopsy, when done, can show the same type of lipid-laden inclusion bodies found in nerve tissue, reinforcing that the mechanism is the same: amiodarone disrupts the cells’ ability to process fats, and any tissue with active lipid metabolism is a potential target.
For patients and clinicians, the practical implication is that weakness out of proportion to sensory symptoms should not be dismissed. If your feet are only mildly numb but your legs feel profoundly weak, that pattern should prompt investigation for concurrent muscle involvement, which may affect rehabilitation planning and recovery expectations.